Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cutting Edge Information
$20B in cardiovascular drug revenues soon subject to patent expiration
April 26th, 2005
More than $20 billion in major cardiovascular drug revenues will be exposed to patent expiration in the next 3 to 5 years, according to a report by business intelligence firm Cutting Edge Information. The report, entitled "Cardiovascular Marketing: Budgets, Staffing and Strategy," highlights the necessity of being able to adapt to the rapid and constant change seen in the pharmaceutical cardiovascular market. Pharmaceutical companies spend more to support a cardiovascular compound's development and commercialization than they do on any other therapeutic products. Among top drug makers, sales from cardiovascular medicines may contribute anywhere from...
Source: Cardiovascular Business Week (2005-04-26)
|
